TP53拷贝数与蛋白表达在急性髓系白血病各风险类别中提示突变状态
该研究分析了528例急性髓系白血病(AML)患者的TP53突变状态、拷贝数(CN)和蛋白表达数据,发现70.2%的TP53突变AML病例存在TP53 CN缺失,且这些病例携带更多有害突变;在TP53 CN完整的患者中,5/32(15.6%)存在拷贝中性杂合性缺失。免疫组化检测的突变p53蛋白表达模式可整合TP53突变和等位基因状态,不受CN状态影响。
要点
- TP53突变AML中70.2%存在TP53拷贝数缺失,且与更多有害突变相关。
- TP53拷贝数完整的AML患者中5/32(15.6%)存在拷贝中性杂合性缺失。
- 免疫组化p53表达可提示突变状态,不受TP53拷贝数状态影响。
核心结论
- 综合分子和蛋白水平的TP53分析可为细化AML患者风险分层提供依据。
研究设计与样本
- 研究分析了528例AML患者的TP53突变状态、拷贝数和蛋白表达数据,涵盖治疗与未治疗患者。
主要发现
- 在TP53突变AML病例中,70.2%存在TP53拷贝数缺失,这些病例携带更多有害TP53突变。
- 在TP53拷贝数完整的AML患者中,5/32(15.6%)存在拷贝中性杂合性缺失。
- 免疫组化检测的突变p53蛋白表达模式可整合TP53突变和等位基因状态,且不受TP53拷贝数状态影响。
- TP53突变AML的共突变谱主要涉及表观遗传调控基因(DNMT3A和TET2)、RAS/MAPK信号通路基因(NF1、KRAS/NRAS、PTPN11)和RNA剪接基因(SRSF2)。
临床怎么用
- 作者认为,基于整合分子和蛋白水平的TP53分析可细化AML患者风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutant TP53 is an adverse risk factor in acute myeloid leukemia (AML), but large-scale integrated genomic-proteomic analyses of TP53 alterations in patients with AML remain limited. We analyzed TP53 mutational status, copy number (CN), and protein expression data in AML (N = 528) and provide a compilation of mutation sites and types across disease subgroups among treated and untreated patients. Our analysis shows differential hotspots in subsets of AML and uncovers novel pathogenic variants involving TP53 splice sites. In addition, we identified TP53 CN loss in 70.2% of TP53-mutated AML cases, which have more deleterious TP53 mutations, as well as copy neutral loss of heterozygosity in 5/32 (15.6%) AML patients who had intact TP53 CN. Importantly, we demonstrate that mutant p53 protein expression patterns by immunohistochemistry evaluated using digital image-assisted analysis provide a robust readout that integrates TP53 mutation and allelic states in patients with AML. Expression of p53 by immunohistochemistry informed mutation status irrespective of TP53 CN status. Genomic analysis of comutations in TP53-mutant AML shows a muted landscape encompassing primarily mutations in genes involved in epigenetic regulation (DNMT3A and TET2), RAS/MAPK signaling (NF1, KRAS/NRAS, PTPN11), and RNA splicing (SRSF2). In summary, our data provide a rationale to refine risk stratification of patients with AML on the basis of integrated molecular and protein-level TP53 analyses.
引用
- Tashakori M, Kadia T, Loghavi S, et al. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022. PMID: 35390143. doi:10.1182/blood.2021013983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。